In bladder and triple-negative breast (a subtype of breast cancer with very poor prognosis) cancer [32], Prx4 was associated with a poor survival and its selective inhibition may serve as additional option for treatment of bladder cancer [33]. Here, PRDX4 is linked to breast carcinoma.